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Available online 18 May 2016Aims: Subclinical diastolic dysfuntion in patients with preclinical heart failure with preserved ejection fraction
(HFpEF) has been demonstrated in patients with Marfan syndrome (MFS). We investigated the relationship be-
tween diastolic dysfunction and NT-proBNP levels in patients with MFS.
Methods and results: NT-proBNP, C-reactive protein (CRP) and diastolic function were assessed in 217 patients
with MFS (31 ± 16 y, 110 f. and in 339 patients referred for suspected MFS in whom the diagnosis was ruled
out according to the Ghent nosology (30± 15 y, 154 f). Assessment of cardiovascular remodeling, diastolic func-
tion in echocardiography, andNT-proBNPwas analyzedwith univariate analysis andmulti-parameter analysis of
covariance (MANCOVA). NT-proBNP was 70.6 ± 74.8 pg/ml in patients with Marfan syndrome and 58.4 ±
100.3 pg/ml in controls (p=0.002, Kolmogorov–Smirnov). Therewere signiﬁcant intergroupdifferences regard-
ing end-diastolic left ventricular volume (p b 0.001), and aortic diameter (p b 0.001). The ratio of early diastolic
mitral ﬂow velocity (E) to early relaxation velocity in tissue Doppler (e′), E/e′ (p b 0.001)was signiﬁcantly higher
in patients with Marfan syndrome than in controls, whereas e′ (p b 0.001) and the ratio of E to inﬂow velocity
during atrial contraction (A), E/A (p = 0.012) was signiﬁcantly lower. Besides age and gender, diagnosis of
MFS, diastolic function (e′ and E/e′), Z-Score of aortic diameter, and left ventricular size were identiﬁed as signif-
icant independent parameters with impact on NT-proBNP levels.
Conclusions:MFS patients presenting with normal ejection fraction show disturbed diastolic function and higher
NT-proBNP levels,which is partly explainedby aortic Z-score. Assessment of diastolic function andNT-proBNP levels
may therefore detect early abnormalities and guide surveillance and preventionmanagement of patients withMFS.







Marfan syndrome is an autosomal, dominantly inherited disorder of
connective tissue characterized by a high degree of clinical variability
[1]. Although complications can involve the eye, the lung and the skele-
ton, the premature mortality of untreated patients results almost exclu-
sively from cardiovascular complications, including aortic dissection
and rupture [2]. Primary cardiomyopathy has been described in individ-
uals withMFS [3]. Classical MFS is caused by heterozygousmutations in
the gene coding for ﬁbrillin-1 [4]. Fibrillins aremajor components of the
microﬁbrils of the extracellular matrix. Microﬁbrils regulate the activity
of transforming growth factor-β (TGF-β), which is associated with larg-
er aortic diameters [5], proﬁbrotic processes in heart failure and areerlin, Augustenburger Platz 1,
d Ltd. This is an open access article uinvolved in myocardial remodeling processes [6]. Current treatment
focusses on aortic dilation as a mortality-related end-point [7,8].
B-type natriuretic peptide (BNP) is a cardiac neurohormone synthe-
sized mainly by ventricular myocytes as a nonspeciﬁc response to wall
stress [9]. Brain natriuretic peptide (BNP) opposes TGF-β-regulated
gene expression related to ﬁbrosis and myoﬁbroblast conversion [10].
The N-terminal prohormone of BNP (NT-proBNP) is used as a diagnostic
marker for cardiac insufﬁciency [11], ventricular dysfunction [12,13],
and aortic dissection [14]. NT-proBNP levels correlate positively with
age [15], sex, and negatively with body mass index (BMI) and can be
used to rule out heart failurewith preserved or reduced ejection fraction
(HFpEF, HFrEF) with similar accuracy [16].
The aim of the present study was to evaluate left ventricular diastolic
function, type of cardio-vascular hypertrophy and NT-proBNP levels in
out-patients with MFS and a control group with similar clinical manifes-
tations referred for evaluation of suspected MFS in whom the diagnosis
was ruled out. We hypothesized that subclinical diastolic dysfunction innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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elevated NT-proBNP levels are more frequent in patients with MFS and
investigated the impacting factorson NT-proBNP levels in these patients.
2. Methods
2.1. Study design and patient population
The study is a monocentric consecutive cohort study of 863 patients
seen in our Marfan clinic between 1/2010 and 7/2015. The diagnosis of
Marfan syndromewas based on the revised Ghent nosology [17] includ-
ing molecular genetic analysis. Clinical assessment according to the
Ghent criteria was performed in all patients. All patients were routinely
examined in our specialized multidisciplinary Marfan clinic. Patients
that did not fulﬁll the Ghent criteria of MFS were used as controls.
Exclusion criteria were history of cardiac surgery or aortic dissection
at any time, mitral or aortic regurgitation, Loeys-Dietz-Syndrome, no
deﬁnite diagnosis, and incomplete dataset (Fig. 1). No patient in this co-
hort was diagnosed with atrial ﬁbrillation.
2.2. Clinical examination
History, physical examination, genetic testing, laboratory tests, or-
thopedic and ophthalmologic counseling and cardiovascular imaging
were performed according to current recommendations. BloodFig. 1. Patient exclusion ﬂow-chart. We analyzed 863 individual patients from 1/2010
through 7/2015. We excluded 238 patients because they had had cardiac surgery at
some time in the past, and four patients that had experienced a type-B aortic dissection
which was treated conservatively. Any patient with more than mild aortic or mitral
regurgitation was excluded as well, as were patients who were diagnosed with Loeys-
Dietz-Syndrome. Seventeen patients had incomplete datasets. The remaining 556
patients consisted of 217 with MFS, and 339 controls.creatinine, C-reactive protein and NT-proBNP levels were collected as
a part of routine laboratory examination. Children were deﬁned as pa-
tients with age b 18 years.
Two-dimensional, pulsed, and color-Doppler and color tissue-
Doppler echocardiograms were acquired using phased array probes on
a Vivid 7 VingmedGeneral Electric Ultrasound scanner (GEVingmedUl-
trasound Horton Norway) following a standardized protocol. M-mode
and two dimensional recordings just beneath the mitral leaﬂet tips in
the long axis for at least 3 beats were used for linear measurements.
Left ventricular end-diastolic diameter (LVEDD), left ventricular end-
systolic diameter (LVESD), thickness of the posterior wall (PWD) and
the septum (IVD) were measured and fractional shortening (FS), left
ventricular end-diastolic volume (LVEDV), and ejection fraction (EF) ac-
cording to the Teichholz' equation [18], relative wall thickness (RWT)
and LVmass (cube formula)were calculated according to recent recom-
mendations on chamber quantiﬁcation [19]. LV-geometry was deﬁned
according to the above recommendations. Left atrial diameter, aortic
root diameters, early diastolicmitral ﬂowvelocity (E) and the inﬂowve-
locity during atrial contraction (A), as well as early relaxation velocity in
tissue Doppler (e′, as mean of septal and lateral e′) were measured, and
the E/A and E/e′ ratioswere calculated. Z-scoreswere calculated for aor-
tic diameter [20]. Aortic or mitral regurgitation and mitral valve pro-
lapse were graded according to recommendations for assessment of
valvular regurgitation [21].
2.3. NT-proBNP measurement
Venous bloodwas collected by peripheral venous puncture as part of
the routine clinical evaluation in an ammonium-heparin monovette
(Sarstedt, Nuembrecht, Germany). Plasma was separated by centri-
fugation at 4000 rpm (2700 ×g) at 4 °C. Aliquots were stored at
−80 °C and thawed immediately prior to NT-proBNP determination.
Measurements were performed with a non-competitive sandwich
electrochemiluminescent immunoassay (ECLIA) on an Elecsys Modular
E 170 platform (Roche Diagnostics, Mannheim, Germany).
2.4. Statistical analysis
SPSS® Statistics version 23, (IBM® corporation) was used. Continu-
ous data are given as mean ± standard deviation. Categorical data are
presented as percentages and analyzed by cross-table analysis. Since
the NT-proBNP data were not normally distributed and cover a large
range, a non-parametric test (Kolmogogorov–Smirnov) and logarithmic
transformation were used as appropriate. Signiﬁcance level was 0.05.
Binary cluster analysiswas used to identifymorphological and function-
al cardiac features that are characteristic for group differences. Univari-
ate linear regression with single covariates was used to pre-select
cofactors and covariates for linear modeling by multiple covariate
analysis of variance (MANCOVA) using stepwise forward and backward
selection.Medical treatmentwas excluded from themultivariate analy-
sis in order to avoid bias, as any association could be caused by
diagnosis-associated treatment strategy.
2.5. Ethical standards
This study complieswith the requirements of our institutional Ethics
Committee Review Board and is in compliance with the Helsinki stan-
dards of human medical studies. All patients gave informed consent.
3. Results
For this studywe recruited 863 patients seen in ourMarfan outpatient
clinic. Because NT-proBNP levels are known to be raised after surgery or
aortic dissection [14,22], 238 patients were excluded because they had
had cardio-vascular surgery at any time before. Four additional who




Diagnosis MFS 0.025 13.83 b0.001
Age 0.15 96.80 b0.001
Gender 0.180 119.75 b0.001
MVP 0.021 11.62 0.001
HTN 0.016 8.47 0.004
Z-score aorta 0.018 10.11 0.002
LA 0.000 0.02 ns
iEDV 0.007 3.58 ns
E 0.000 0.14 ns
A 0.035 19.36 b0.001
E/A-ratio 0.015 7.80 0.005
e′ Sept 0.042 20.18 b0.001
e′ Lat 0.029 13.84 b0.001
e′Mean 0.040 19.24 b0.001
E/e′-ratio 0.058 28.15 b0.001
Mild AR 0.029 16.10 b0.001
Mild MR 0.028 15.84 b0.001
CRP 0.023 9.61 0.002
BSA all 0.009 4.95 0.027
BSA adult females 0.005 1.14 ns
BSA adult males 0.025 5.37 0.021
BSA children b18 yrs 0.160 22.47 b0.001
BMI 0.000 0.02 ns
BMI children b18 yrs 0.067 8.51 0.004
Height 0.022 12.22 0.001
Height all 0.019 8.27 0.004
Height adult females 0.021 4.47 0.036
Height adult males 0.038 8.11 0.005
Height children b18 yrs 0.16 22.34 b0.001
Weight all adults 0.004 1.90 ns
Weight children b18 yrs 0.15 20.25 b0.001
Beta blockers 0.059 29.20 b0.001
Beta blockers, b18 yrs 0.027 2.733 ns
Losartan 0.026 12.24 0.01
Losartan, children 0.009 0.09 ns
Legend: MVP, mitral valve prolapse; HTN, Hypertension; Z-score aorta, normalized diam-
eters of aortic diameter; LA, left atrium; iEDV, indexed end-diastolic volume; BSA, body
surface area; E, early diastolic mitral ﬂow velocity; A, inﬂowvelocity during atrial contrac-
tion; e′ sept, e′ lat, e′mean, septal and lateral early relaxation velocity in tissue Doppler,
and their mean; E/e′, ratio of E, early diastolic mitral ﬂow velocity, over e′; MR, mitral re-
gurgitation; AR, aortic regurgitation; CRP, C-reactive protein; BSA, body surface area; b18,
under 18 years of age; ns, not signiﬁcant.
Table 1
Demographic data and measurements.
MFS Control Signiﬁcance
Mean, ±SD Mean, ±SD p
Age (yrs) 31.05 ± 16.16 30.27 ± 14.61 ns
HR (bpm) 71.40 ± 11.85 72.86 ± 13.46 ns
Syst BP (mm Hg) 125.08 ± 22.50 122.96 ± 17.98 ns
Diastol BP (mm Hg) 75.21 ± 12.70 74.76 ± 12.06 ns
MAD (mm Hg) 91.90 ± 14.21 90.33 ± 12.72 ns
Height (cm) 179.95 ± 19.37 177.60 ± 15.40 ns
Weight (cm) 71.32 ± 22.46 67.23 ± 17.33 0.023
BSA 1.89 ± 0.38 1.83 ± 0.28 0.036
BMI 21.46 ± 4.8 21.17 ± 4.54 ns
LVEDD (mm) 50.52 ± 7.06 48.18 ± 5.83 b0.001
LVESD (mm) 30.93 ± 5.91 29.38 ± 4.79 0.001
IVSd (mm) 10.45 ± 2.67 10.00 ± 2.35 0.015
PWd (mm) 9.12 ± 2.23 8.92 ± 2.01 ns
RWT 0.39 ± 2.09 0.39 ± 0.08 ns
FS (%) 38.44 ± 7.16 38.83 ± 6.79 ns
EF (%) 67.84 ± 8.90 68.69 ± 8.31 ns
EDV (ml) 124.70 ± 40.94 111.28 ± 30.38 b0.001
iEDV 66.10 ± 16.94 60.49 ± 12.72 b0.001
Aortic diameter (mm) 38.10 ± 6.71 32.41 ± 6.46 b0.001
Z-score aorta 1.99 ± 2.14 1.1 ± 1.51 b0.001
Left atrium (mm) 32.35 ± 7.15 31.83 ± 6.18 ns
E 76.51 ± 19.66 83.80 ± 19.23 b0.001
A 57.13 ± 16.42 55.94 ± 15.26 ns
E/A ratio 1.43 ± 0.48 1.59 ± 0.52 b0.001
e′ Sept 10.71 ± 2.95 13.16 ± 3.19 b0.001
e′ Lat 12.37 ± 4.1 15.99 ± 4.21 b0.001
e′Mean 11.54 ± 3.3 14.58 ± 3.38 b0.001
E/e′ ratio 6.84 ± 1.95 5.88 ± 1.45 b0.001
NT-proBNP 70.55 ± 74.76 58.35 ± 101.09 b0.002*
ln NT-proBNP 3.78 ± 1.02 3.5 ± 1.05 0.001
Creatinine 0.79 ± 0.14 0.77 ± 0.17 ns
CRP 0.22 ± 0.33 0.2 ± 0.31 ns
IVRTm 81.95 ± 18.40 71.56 ± 14.74 0.009
Legend: * Kolmogorov–Smirnov test. Results are represented as mean ± standard
deviation(SD). BMI, bodymass index; BSA, body surface area; syst BP and dias BP, systolic
and diastolic blood pressure, MAD, mean arterial blood pressure; LVEDD, LVESD, left ven-
tricular end-diastolic and end-systolic diameter, FS, fractional shortening; EF, ejection frac-
tion; EDV, end-diastolic volume, EDVI, indexed end-diastolic volume; E, early diastolic
mitral ﬂow velocity; A, inﬂow velocity during atrial contraction; E/A ratio of E over A, e′
sept, e′ lat, septal and lateral early relaxation velocity in tissue Doppler; E/e′, ratio of E
over e′; NT-proBNP, N-terminal pro hormone of brain natriuretic peptide; Ln NT-proBNP,
natural logarithm of NT-proBNP; CRP c-reactive protein; IVRTm, mean isovolumetric re-
laxation time. (Table 2) Univariate linear analysis, LnBNP.
17P. Gehle et al. / IJC Heart & Vasculature 12 (2016) 15–20with diagnosis of Loeys-Dietz-Syndrome, one patient in whom deﬁnite
diagnosis could not be established, 13 with more than mild aortic regur-
gitation, 18who had amore thanmild degree ofmitral regurgitation, and
16 patients in whom datasets were incomplete, were excluded as well.
We investigated NT-proBNP levels and echocardiographic diastolic func-
tion parameters in 217 (110 females) patients with MFS. As a control
group we investigated 339 (154 females) patients seen for suspected
MFS in whom the diagnosis was subsequently ruled out (Table 1).
There were no signiﬁcant group differences regarding age, height,
BMI, blood pressure and heart rate.Weightwas slightly but signiﬁcantly
higher (p = 0.023) in patients with MFS.
There were about 20% children with MFS and 17% among controls
(n.s). There was a trend to more males presenting with MFS (50% vs.
45% males). Both trends were not signiﬁcant in cross-table analysis.
More patients were medically treated in the MFS group (50% vs. 26%,
p b 0.001). Especially treatment with angiotensin II receptor blockers
(ARBs) (25% vs. 3%, p b 0.001) or angiotensin converting enzyme
(ACE) inhibitors (6% vs. 2%, p b 0.001) and beta-blockers (16% vs. 5%,
p b 0.001) were more frequent in patients with MFS. Treatment with
beta-blockers was associated with signiﬁcantly increased NT-proBNP
levels in both groups (p b 0.001). Mitral valve prolapse (80% vs. 44%,
p b 0.001), mild mitral regurgitation (11% vs. 4%, p b 0.001) and mild
aortic regurgitation (20% vs. 7%, p b 0.001)were foundmore often in pa-
tients with MFS.3.1. Echocardiography and laboratory values
Chamber dimensions, wall thickness and parameters of systolic and
diastolic function were within normal range in both groups. There were
no signiﬁcant group differences for, left atrial size, fractional shortening
(FS: 39 ± 7%), ejection fraction (EF: 68 ± 9%), and mitral inﬂow
velocities(see Table 1). Aortic diameter, end-diastolic left ventricular
(LV) (indexed) volumes and masses, end-systolic and end-diastolic di-
ameter, septal thickness, and the E/e′ ratio (p b 0.001)were signiﬁcantly
higher in patients with MFS than in controls, while e′ (p b 0.001) and
the E/A ratio (p = 0.001) were signiﬁcantly reduced. Aortic diameters
and their z-scores (p b 0.001) were – as expected – larger in MFS pa-
tients. NT-proBNP was 71 ± 75 pg/ml in patients with MFS and 58 ±
100 pg/ml in controls (p b 0.002; Kolmogorov–Smirnov test)
(Table 1). CRP and creatinine levels did not differ signiﬁcantly.3.2. Type of cardiovascular hypertrophy in MFS
There weremore dilated (24% vs. 14%, p b 0.001) and hypertrophied
(35% vs. 18%, p b 0.001) ventricles in patients with MFS, however. The
groups did not differ with respect to type of hypertrophic remodeling
comprising about 30% excentric cases in both groups. Impaired ejection
fraction was found in 21 patients with MFS and 19 controls.
In binary two-step cluster analysis larger aortic diameter (38 ±
6mm vs. 32 ± 6mm, p b 0.001), and reduced early relaxation in tissue
18 P. Gehle et al. / IJC Heart & Vasculature 12 (2016) 15–20Doppler (e′) (11.5± 3.3 cm/s vs. 14.6 ± 3.4 cm/s, p b 0.001) turned out
to be the best classifying variables.
3.3. Analysis of cofactors and covariates predicting NT-proBNP by linear
regression modeling
For linear modeling a logarithmic transformation of NT-proBNP was
used.
Age (p b 0.001), gender (p b 0.001), height (p b 0.001), BSA
(p b 0.001), CRP (p = 0.001), diagnosis of Marfan syndrome (p =
0.001), A-wave (p b 0.001), E/A ratio (p = 0.017), E/e′ ratio
(p b 0.001), tissue Doppler measurements of septal e′ (p b 0.001) and
lateral e′ (p = 0.014) and its calculated average e′ mean (p = 0.001),
aortic regurgitation (p= 0.003), mitral regurgitation (p b 0.001), mitral
valve prolapse (p b 0.028), aortic z-score (p = 0.002), indexed end-
diastolic volume (iEDV, p = 0.032), LV hypertrophy (p = 0.003) and
concentric type of hypertrophy (p = 0.039) but not LV linear dimen-
sions or ejection fraction or creatininewere signiﬁcant covariates or co-
factors in predicting NT-proBNP by univariate linear analysis (see
Table 2). The paradoxically negative correlation of height with NT-
proBNP in the total sample is explained by hidden effects of genderFig. 2. Regression analysis of height. A negative regression in all patients (not shown) and adul
(B) and the higher NT-proBNP levels in females (C, D), who are smaller thanmales. This outweiand inclusion of children as demonstrated in Fig. 2. The interaction of
gender and age on e' is illustrated in Fig. 3.
In a ﬁrst step of multiple parameter univariate ANCOVA
(MANCOVA) linear analysis, gender (p b 0.001), age (p b .0.001), height
(p= 0.001), and diagnosis of MFS (p= 0.001) were found to be signif-
icant covariates and cofactors of NT-proBNP (F-value of model 52, R2 =
0.27). The diagnosis of MFS was a signiﬁcant cofactor for NT-proBNP
levels, as was e′, which can be regarded as a good indicator of diastolic
function. MFS patients had signiﬁcantly lower e′ values as compared
to controls. Aortic z-score was signiﬁcanty larger in the MFS group.
Therefore, e′ or aortic diameter z-score were potential confounders.
However, the diagnosis of MFS remained a signiﬁcant cofactor even
after the aortic z-score was introduced into the model, suggesting that
aortic z-score has an inﬂuence on NT-proBNP levels indepently of the
diagnosis of MFS. Finally inMANCOVAmodel adjusted for demographic
parameters we investigated which parameters explain the effects of di-
agnosis MFS (F = 10.05) on NT-proBNP. We found that parameters of
diastolic cardiac function as E/e′ (F = 10.92) and e′mean (F = 11.72),
iEDV (F = 7.70), and aortic diameter (F = 10.04) were signiﬁcant and
replaced diagnosis of MFS best. This analysis suggests that the impact
of MFS on NT-proBNP is largely mediated by impaired diastolicts (A) is explained by the higher NTproBNP levels younger and therefore smaller children
ghs the effect of greater height of patients withMFSwho do have higher NT-proBNP levels.
Fig. 3. Box plot of early relaxation velocity (e′) in tissueDoppler (average of e′ septal and e′
lateral) on top and ratio of aortic diameter to e′ at bottom for controls and patients with
MFS stratiﬁed with respect to gender and age below 16 years. Lines: median, boxes: 75%
conﬁdence interval (CI), whiskers: 95% CI.
19P. Gehle et al. / IJC Heart & Vasculature 12 (2016) 15–20relaxation as well as aortic dilatation, and to a smaller amount by other
factors such as concentric hypertrophy and mitral regurgitation.
4. Discussion
This is the largest clinical study on NT-proBNP levels and diastolic
function parameters expressing a subclinical intrinsic cardiomyopathy
in patients with MFS. Subclinical cardiomyopathy in patients with
MFS has been found in several clinical echocardiographic [23–25] and
magnetic resonance and combined imaging studies [3,6,26]. Diastolic
dysfunction has been described to be impaired in MFS [27,28] but NT-
proBNP measurements in this context have not been published before.
In agreementwith these studieswe found a relatively impaired diastolic
left ventricular relaxation as compared to controls. Left ventricular
dilatation and hypertrophy without differences in type of hypertrophic
remodeling and as expectedly aortic dilatation were more often seen in
ths MFS group.
Moreover, in this study we demonstrate signiﬁcantly higher NT-
proBNP levels in patients with MFS as compared to control patients
with similar phenotype in whom MFS had been ruled out. This has not
been described before. The relative elevation of NT-proBNP in MFS as
opposed to controls was not explained by known demographic
cofactors and covariates. The strongest predictor of NT-proBNP
elevation was diastolic function follwed by Z-score of aortic diameter
suggesting that primary disease related cardiomyopathy in MFS mani-
fests predominantly as diastolic relaxation impairment. Patients with
valvular dysfunction with left ventricular loading were excluded from
our study. Therefore, our results might be attributed to a MFS-related
myocardial impairment as would be the case in primary cardiomyopa-
thy, which in turn leads to diastolic dysfunction and dilatation of cardiac
cavities and large vessels with resultant NT-proBNP elevation.
According to the Laplace law aortic wall stress is proportional to the
aortic diameter. Our ﬁnding of a signiﬁcant and independent correlation
of z-scores of aortic diameters and NT-proBNP therefore may be in part
caused by ventricular afterload mismatch resulting from increased aor-
tic stiffness. Thus somemodulating role of the aortic pathology inMFS in
the development of cardiomyopathy in patients with MFS is likely.
Afterload impedancemismatch due to higher aortic stiffness may be re-
lated to decreased aortic elastic properties in young patients with MFSas compared to a control group [29]. Fibrillin-1 deﬁciency activates
TGF-ß signaling pathways, leading to elevated collagen synthesis and
matrix metalloproteinase-mediated disruption of the elastic ﬁbers in
the vessel wall, thereby increasing aortic stiffness and decreasing
vasoreactivity [30]. Increased levels of TGF-ß have been detected in
aneurysmatic aortic wall of patients with MFS [31] and circulating
TGF-ß has been proposed as prognostic biomarker in MFS [5,32].
Treatment with beta-blockers was associated with signiﬁcantly in-
creased NT-proBNP levels in both groups (p b 0.001) as has been
descibed before [33,34]. Impairment of renal function has been shown
to increase NT-proBNP levels [35]. No patient in our study had severe
renal dysfunction. Blood creatinine levels were investigated and did
not differ between groups and were not signiﬁcant in linear modeling.
5. Limitations and conclusions
This is a non-randomized retrospective consecutive cohort study
with several limitations. Data on potential clinical correlates of diastolic
dysfunction, such as exercise intolerance, were not collected, and echo-
cardiographic evaluationwas performed using aminimal data set with-
out sophisticated echocardiographic data on diastolic and systolic
biventricular function as well as left and right atrial volumes, aortic
compliance. Circulating TGF-ß and matrix metalloproteinases were
not measured. Nonetheless, our study has shown for the ﬁrst time
that circulating NT-proBNP levels are relatively increased in patients
withMFS. Presumably this observation is related to the presence of sub-
clinical diastolic cardiomyopathy in MFS, which conceivably could be
related to the underlying genetic defect in MFS or could be a secondary
effect of the increased afterload associated with increased aortic stiff-
ness or both. Further researchwill be needed to characterize a potential
clinical role of NT-proBNP measurements in the management of per-
sons with MFS, and to better characterize the prevalence and clinical
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